Clinical trials: Left Ventricular Fibrosis
Mitral Valve Prolapse, Left Ventricular Fibrosis
PRIMARY Ancillary Substudy
The PRIMARY trial (NCT05051033), which compares mitral valve repair (MVr) to transcatheter-edge-to-edge-repair (TEER), offers a platform for conducting mechanistic studies to develop early insights into the pathophysiological…
- Conditions
- Mitral Valve Prolapse, Left Ventricular Fibrosis, Ventricular Arrhythmias
- Trial name
- NCT07103733
- Testing
- Cardiac Magnetic Resonance Imaging, ZioPatch Monitoring, Myocardial Tissue Biopsy
- Where
- 25 sites in United States, Germany and 1 more
- Volunteers
- 250 people
- Sponsor
- Annetine Gelijns
HFpEF, LVDD
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with [angiotensin receptor/neprilysin inhibitor [ARNI]…
- Conditions
- HFpEF, LVDD, Myocardial Fibrosis
- Trial name
- NCT06655480
- Testing
- [ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker]
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Hypertension
The COlchicine HypERtENsion Trial
The purpose of this study to investigate the effects of colchicine on measures of vascular and cardiac function in patients with hypertension.
- Trial name
- COHERENT (NCT04916522)
- Testing
- Colchicine
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Herlev and Gentofte Hospital
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Cardiac Structure and Function in Patients with Cystic Fibrosis
In a prospective observational cohort study (n = 100), the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and cystic fibrosis genotype and severity and determine whether these…
- Conditions
- Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis, Pulmonary, Cystic Fibrosis of Pancreas
- Trial name
- NCT06084468
- Where
- 2 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Herlev and Gentofte Hospital
Aortic Stenosis, Myocardial Fibrosis
Mechanism of Decompensation Evaluation - Aortic Stenosis
Aortic stenosis is the most common heart valve disease requiring intervention in high income countries. It is characterised by progressive valvular thickening, and restriction as well is hypertrophy and fibrosis of the left…
- Conditions
- Aortic Stenosis, Myocardial Fibrosis, Left Ventricular Hypertrophy
- Trial name
- MODE-AS (NCT03332745)
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Edinburgh
Left Ventricular Hypertrophy, Hypertension
Response of the Myocardium to Hypertrophic Conditions in the Adult Population
Hypertension and aortic stenosis are the two leading conditions that cause thickening of the heart muscles (left ventricular hypertrophy). Left ventricular hypertrophy is initially adaptive to maintain optimal heart function.
- Conditions
- Left Ventricular Hypertrophy, Hypertension, Myocardial Fibrosis
- Trial name
- NCT02670031
- Testing
- Cardiovascular Magnetic Resonance, Echocardiogram, Electrocardiogram
- Where
- Singapore
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Heart Centre Singapore
Aortic Valve Stenosis, Left Ventricular Dysfunction
Better Patient Selection to Transcatheter Aortic Valve Implantation
This study evaluates whether a preoperative assessment of myocardial contractile reserve by tissue Doppler Imaging and myocardial fibrosis by cardiac magnetic resonance imaging (MRI) can enhance the patient selection and risk…
- Conditions
- Aortic Valve Stenosis, Left Ventricular Dysfunction, Myocardial Fibrosis
- Trial name
- NCT03107923
- Testing
- Dobutamine stress test
- Where
- 2 sites in Norway
- Volunteers
- 103 people
- Sponsor
- Oslo University Hospital
Atrial Remodeling, Myocardial Dysfunction
Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation
Sacubitril-valsartan, an Angiotensin Receptor Blocker-Neprilysin Inhibitor (ARNI), currently marketed for the management of heart failure, has been shown to reduce cardiovascular morbidity and mortality in stage C heart failure…
- Conditions
- Atrial Remodeling, Myocardial Dysfunction, Left Ventricular Remodeling, Left Ventricular Diastolic Dysfunction
- Trial name
- PARABLE (NCT04687111)
- Testing
- Sacubitril-Valsartan, Valsartan
- Where
- 2 sites in Ireland
- Volunteers
- 250 people
- Sponsor
- Mark Ledwidge
Dilated Cardiomyopathy, Left Ventricular Systolic Dysfunction
Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy
CMR GUIDE DCM is a randomized controlled trial with a registry for non-randomized patients. Patients enrolled will have non-ischemic cardiomyopathy (NICM) with mild to severe Left Ventricular (LV) systolic dysfunction with…
- Conditions
- Dilated Cardiomyopathy, Left Ventricular Systolic Dysfunction, Fibrosis Myocardial
- Trial name
- CMR GUIDE DCM (NCT03993730)
- Testing
- ICD, ILR
- Volunteers
- 1,880 people
- Sponsor
- Flinders University
Aortic Valve Stenosis, Heart Failure
Left Atrial Volume Index in Asymptomatic Aortic Stenosis
Aortic stenosis results in increased filling pressures of the heart. Size and function of the left atrium may be a marker for more advanced heart disease (heart failure) in patients with severe aortic stenosis, not presenting any…
- Trial name
- LAVIAS (NCT02395107)
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Hypertrophic Cardiomyopathy
Pirfenidone to Treat Hypertrophic Cardiomyopathy
This study will examine the effectiveness of the drug pirfenidone (Deskar) in improving heart function in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT00011076
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)